Should You Continue to Hold ACHC Stock at an 18.17X P/E Valuation?

Where Do Estimates for ACHC Stand?

The consensus mark for 2026 earnings is pegged at $1.54 per share, which has moved up 4 cents over the past 30 days. The consensus estimate for revenues is pegged at $3.43 billion, indicating 3.5% year-over-year growth. ACHC’s bottom line surpassed estimates in each of the trailing four quarters, the average surprise being 47%.

Acadia Healthcare Company, Inc. Price, Consensus and EPS Surprise

Factors Driving ACHC's Performance

Acadia is making solid progress in ramping up its recently opened facilities, with revenues and facility-level EBITDA from the 2023-2026 facility cohorts exceeding expectations in the second quarter. It remains confident in generating $200 million of incremental adjusted EBITDA compared with 2025 as these facilities mature. Acadia also raised its 2026 adjusted EBITDA guidance to $590-$615 million from $580-$615 million, supporting its outlook for continued earnings growth.

Acadia continues to expand its network through joint ventures, de novos and bed additions. The company added more than 300 beds during the first half of 2026, including 240 licensed beds from newly constructed facilities in the second quarter. Acadia remains on track to add 500-600 beds in 2026, positioning it to capitalize on sustained behavioral healthcare demand.

Net cash provided by operating activities totaled $223.6 million in the first six months of 2026 compared with $145.0 million in the prior-year period. The company ended the quarter with $171.3 million in cash and cash equivalents and $669.8 million available under its revolving credit facility. Its long-term debt-to-capital ratio of 56.7% remains lower than the industry average of 73.2%, reflecting relatively healthy financial positioning. The company expects positive free cash flow generation in the second half of 2026 as capital expenditures decline to an estimated $235-$255 million. Higher operating cash flow and lower CapEx support financial flexibility.

Risk Factors

Acadia Healthcare continues to face elevated operating and legal expenses, which are pressuring profitability. In the second quarter of 2026, total expenses increased to $843.8 million from $819.2 million in the prior-year period due to higher salaries, wages, benefits, supply costs and professional fees.

Operating expenses also rose to 97.5% of revenues from 94.2% a year ago. Total operating expenses included a $28.6 million PLGL reserve adjustment; excluding this adjustment, operating expenses increased 3.1% year over year. These higher costs could continue to pressure Acadia’s margins and profitability.

ACHC’s profitability and capital efficiency metrics remain below industry averages, reflecting slower returns from recent expansion initiatives. The company’s trailing 12-month return on equity (ROE) was 6.2%, significantly below the industry average of 24.8%. Return on invested capital (ROIC) was 5.5%, below the industry average of 9.4%, indicating weaker return generation despite substantial investments, strong cash generation and valuable real estate assets.

Stocks to Consider

Some better-ranked stocks in the broader Medical space are Tenet Healthcare Corporation THC and BrightSpring Health Services, Inc. BTSG, both sporting a Zacks Rank #1 (Strong Buy) at present, and LifeStance Health Group, Inc. LFST, carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

The Zacks Consensus Estimate for Tenet Healthcare’s 2026 earnings is pegged at $19.85 per share, which has witnessed six upward revisions in the past 30 days, with no movement in the opposite direction. THC beat earnings estimates in each of the trailing four quarters, with the average surprise being 22.7%. The consensus estimate for 2026 revenues is pinned at $22.13 billion, implying 3.9% year-over-year growth.

The Zacks Consensus Estimate for BrightSpring Health’s 2026 earnings is pegged at $1.78 per share, which has witnessed five upward revisions in the past 30 days, with no movement in the opposite direction. BTSG beat earnings estimates in three of the trailing four quarters and missed once, with the average surprise being 16.1%. The consensus estimate for 2026 revenues is pinned at $15.24 billion, implying 18.1% year-over-year growth.

The Zacks Consensus Estimate for LifeStance Health’s 2026 earnings is pegged at 15 cents per share, which has witnessed two upward revisions in the past 30 days, with no movement in the opposite direction. LFST beat earnings estimates in each of the trailing four quarters, with the average surprise being 166.67%. The consensus estimate for 2026 revenues is pinned at $1.71 billion, implying 19.7% year-over-year growth.

7 Best Stocks for the Next 30 Days

Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."

Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.9% per year. So be sure to give these hand picked 7 your immediate attention. 

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research